newsfilter
← Latest News
ACCESS Newswire·

Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100(R) (Aviptadil)

This new formulation may have important clinical uses for a variety of rare lung diseases GENEVA, SWITZERLAND / ACCESSWIRE / August 3, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seek